Cost Minimization and Budget Impact Analysis of Viscosupplementation with Hylan G-F 20 for the Treatment of Knee Osteoarthrosis from the Perspective of the Public Sector in El Salvador and Panama
Author(s)
Gil Rojas Y1, Castañeda-Cardona C2, Lasalvia P3
1NeuroEconomix, Bogotá, CUN, Colombia, 2NeuroEconomix, Bogotá, D.C., CUN, Colombia, 3NeuroEconomix, BOGOTA, CUN, Colombia
Presentation Documents
OBJECTIVES: The objective of this research was to present a cost minimization (CMA) and budgetary impact analysis(BIA) of 6 mL hylan G-F 20 viscosupplementation for the treatment of knee osteoarthrosis in patients who are not suitable for pharmacological treatment or surgery in El Salvador and Panama. METHODS: Both the CMA and the BIA were developed from the perspective of the public health system. The analysis horizon for CMA was 1 year and for BIA, 5 years. The justification of similar effectiveness and safety between the evaluated intervention and its comparators was based on the published literature. The main parameters of the models were acquisition costs, administration, and the need for retreatment. For the budgetary impact, quantification of the population was based on published epidemiological information and local databases. Costs were reported in US dollars (USD) at 2020 prices. RESULTS: In El Salvador, the expected annual cost with hylan G-F 20 (6 mL) was estimated at $316.9. The savings derived from its use were $ 35.0 (10%) vs. hylan G-F 20 (2 mL) and $ 202.2 (39%) vs. HA. In Panama, the expected annual cost with hylan G-F 20 (6 mL) was estimated at $403.7. The savings derived from its use were $154.6 (28%) vs. hylan G-F 20 (2 mL) and $567.7 (58%) vs. HA. In the budget impact analysis, considering a gradual substitution over 5 years, the introduction of hylan G-F 20 (6 mL) would be associated with savings of $138,513 (2%) in El Salvador and $290,728 (3.6%) in Panama. CONCLUSIONS: Viscosupplementation with hylan G-F 20 (6 mL) in patients with knee osteoarthrosis is a cost-saving alternative when compared to hylan G-F 20 (2 mL) and low molecular weight hyaluronic acid derivatives available in the public health sector in El Salvador and Panama.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSA164
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Medical Devices, Musculoskeletal Disorders